Vor Biopharma Q2 2025 Earnings Report

Vor Biopharma EPS Results

• Actual EPS: -$43.60
• Consensus EPS: -$11.40
• Beat/Miss: Missed by -$32.20
• One Year Ago EPS: N/A

Vor Biopharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vor Biopharma Announcement Details

• Quarter: Q2 2025
• Date: 8/12/2025
• Time: After Market Closes
• Conference Call Date: Tuesday, August 12, 2025
• Conference Call Time: 4:00PM ET

Vor Biopharma (NASDAQ:VOR), Inc. is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Preclinical studies have demonstrated selective resistance of edited HSCs to CD33-directed therapies, allowing concurrent administration of anti-CD33 agents to eliminate malignant cells while preserving healthy hematopoiesis. In addition to VOR33, Vor maintains a discovery pipeline of follow-on candidates targeting other hematologic cancer antigens, as well as programs exploring combination strategies with existing immunotherapies.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vor Biopharma went public in 2021 and collaborates with leading academic medical centers and contract development organizations across the United States. The company is led by President and Chief Executive Officer Sean Nolan, whose previous experience includes senior leadership roles in immuno-oncology and cell therapy development. Vor’s scientific advisory board comprises experts in hematology, stem cell biology, and genome editing, supporting its mission to transform the treatment paradigm for blood cancer patients.